Zacks Investment Research on MSN
AngioDynamics (ANGO) upgraded to buy: Here's why
AngioDynamics (ANGO) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of ...
AngioDynamics reported mixed fiscal 2025 Q1 results. The medical technology company has had some good news recently, though. AngioDynamics continues to expect modest growth for the full year.
Peer-reviewed findings demonstrate high disease control and quality-of-life preservation, supporting shift toward focal therapy in prostate treatment “The publication of the PRESERVE study in European ...
The ALPHA-PE Research Fund Supports Independent, Physician-Led Studies to Advance Real-World PE Evidence The ALPHA-PE Research Fund is designed to support independent, physician-led research ...
AngioDynamics Inc (NASDAQ: ANGO) has reported a Q4 FY23 adjusted EPS of $0.02, in line with the consensus EPS higher than $0.01 a year ago. Q4 sales increased 4.7% Y/Y to $91.07 million, beating the ...
LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, ...
New data finds AlphaVac F1885 System safe in patients with acute intermediate-risk pulmonary embolism (PE) and provides significant improvement in right ventricular function and reduction in clot ...
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, ...
LATHAM, N.Y., March 31, 2026--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s ...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options ...
The adjusted losses that the medical device maker reported for its fiscal Q2 weren't as bad as expected, but its sales weren't as good as expected. The Nanoknife-maker has lost money for five straight ...
AngioDynamics posted Q3 adjusted EPS of $0.03, beating the $(0.13) loss expected. Sales rose 9.2% to $72M, surpassing the $70.3M consensus. Med Tech net sales grew 22.2% to $31.3M, with Auryon up 17.3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results